Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

View/ Open
Issue date
2017Author
Rivero, Antonio
Pérez-Molina, José Antonio
Blasco, Antonio Javier
Arribas, José Ramón
Crespo, Manuel
Domingo, Pere
Estrada, Vicente
Iribarren, José Antonio
Knobel, Hernando
Lázaro, Pablo
López Aldeguer, José
Lozano, Fernando
Moreno, Santiago
Palacios, Rosario
Pineda, Juan Antonio
Pulido, Federico
Rubio, Rafael
de la Torre, Javier
Tuset, Montserrat
Gatell, Josep M.
Suggested citation
Rivero, Antonio;
Pérez-Molina, José Antonio;
Blasco, Antonio Javier;
Arribas, José Ramón;
Crespo, Manuel;
Domingo, Pere;
...
Gatell, Josep M..
(2017)
.
Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Enfermedades Infecciosas y Microbiología Clínica, 2017, vol. 35, núm. 2, p. 88-99.
https://doi.org/10.1016/j.eimc.2016.06.013.
Metadata
Show full item recordAbstract
Introduction: GESIDA and the AIDS National Plan panel of experts suggest preferred (PR),
alternative (AR) and other regimens (OR) for antiretroviral treatment (ART) as initial therapy
in HIV-infected patients for 2016. The objective of this study is to evaluate the costs and the
efficiency of initiating treatment with these regimens. Methods: Economic assessment of
costs and efficiency (cost/efficacy) based on decision tree analyses. Efficacy was defined as
the probability of reporting a viral load <50 copies/mL at week 48, in an intention-to-treat
analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART
and its consequences (adverse effects, changes of ART regimen, and drug resistance studies)
during the first 48 weeks. The payer perspective (National Health System) was applied
considering only differential direct costs: ART (official prices), management of adverse
effects, studies of resistance, and HLA B*5701 testing. The setting is Spain and the costs
correspond to those of 2016. A sensitivity deterministic analysis was conducted, building
three scenarios for each regimen: base case, most favourable and least favourable. Results: In
the base case scenario, the cost of initiating treatment ranges from 4,663 Euros for 3TC +
LPV/r (OR) to 10,894 Euros for TDF/FTC + RAL (PR). The efficacy varies from 0.66 for
ABC/3TC + ATV/r (AR) and ABC/3TC + LPV/r (OR), to 0.89 for TDF/FTC + DTG (PR) and TDF/FTC/EVG/COBI (AR). The efficiency, in terms of cost/efficacy, ranges from 5,280
to 12,836 Euros per responder at 48 weeks, for 3TC + LPV/r (OR) and RAL + DRV/r (OR)
respectively. Conclusion: Despite the overall most efficient regimen was 3TC + LPV/r (OR),
among the PR and AR, the most efficient regimen was ABC/3TC/ DTG (PR). Among the AR
regimes, the most efficient was TDF/FTC/RPV.
Is part of
Enfermedades Infecciosas y Microbiología Clínica, 2017, vol. 35, núm. 2, p. 88-99European research projects
Collections
The following license files are associated with this item:
Related items
Showing items related by title, author, creator and subject.
-
Association of complement receptor 2 polymorphisms withinnate resistance to HIV-1 infection
Herrero, Rocío; Real, Luis M.; Rivero-Juárez, Antonio; Pineda, Juan Antonio; Camacho, Ángela; Macías, Juan; Laplana Lafaja, Marina; Konieczny, Piotr; Márquez, Francisco J.; Souto, Juan Carlos; Soria, José Manuel; Saulle, Irma; Lo Caputo, Sergio; Biasin, Mara; Rivero, Antonio; Fibla Palazón, Joan; Caruz, Antonio (Springer Nature, 2015-03)HIV-1 induces activation of complement through the classical and lectin pathways. However, the virus incorporates several membrane-bound or soluble regulators of complement activation (RCA) that inactivate complement. HIV-1 ... -
Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability
Aguilar-Jiménez, Wbeimar; Zapata, Wildeman; Rivero-Juárez, Antonio; Pineda, Juan Antonio; Laplana Lafaja, Marina; Taborda, Natalia A.; Biasin, Mara; Clerici, Mario; Caruz, Antonio; Fibla Palazón, Joan; Rugeles, Maía T. (Elsevier, 2019)Vitamin D (VitD) may modulate anti-HIV-1 responses modifying the risk to acquire the HIV-1-infection. We performed a nested case-control exploratory study involving 413 individuals; HIV-1-exposed seropositives (cases) and ... -
Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID‑19
Bermejo Martin, Jesús F.; González Rivera, Milagros; Almansa, Raquel; Micheloud, Dariela; Tedim, Ana P.; Domínguez Gil, Marta; Resino, Salvador; Martín Fernández, Marta; Murua, Pablo Ryan; Pérez García, Felipe; Tamayo Lomas, Luis; López Izquierdo, Raúl; Bustamante Munguira, Elena; Aldecoa, César; Gómez, José Manuel; Rico Feijoo, Jesús; Orduña, Antonio; Méndez, Raúl; Fernández Natal, Isabel; Megías, Gregoria; González Estecha, Montserrat; Carriedo, Demetrio; Doncel, Cristina; Jorge, Noelia; Ortega, Alicia; Fuente, Amanda de la; Campo, Félix del; Fernández Ratero, José Antonio; Trapiello, Wysali; González Jiménez, Paula; Ruiz, Guadalupe; Kelvin, Alyson A.; Toloue Ostadgavahi, Ali; Oneizat, Ruth; Ruiz, Luz María; Miguéns, Iria; Gargallo, Esther; Muñoz, Ioana; Pelegrin, Sara; Martín, Silvia; García Olivares, Pablo; Cedeño, Jamil Antonio; Ruiz Albi, Tomás; Puertas, Carolina; Berezo, Jose Ángel; Renedo, Gloria; Herrán, Rubén; Bustamante Munguira, Juan; Enríquez, Pedro; Cicuendez, Ramón; Blanco, Jesús; Abadia, Jesica; Gómez Barquero, Julia; Mamolar, Nuria; Blanca López, Natalia; Valdivia, Luis Jorge; Fernández Caso, Belén; Mantecón, María Ángeles; Motos, Anna; Fernandez Barat, Laia; Ferrer, Ricard; Barbé Illa, Ferran; Torres, Antoni; Menéndez, Rosario; Eiros, José María; Kelvin, David J. (BMC, 2020)Background. COVID-19 can course with respiratory and extrapulmonary disease. SARS-CoV-2 RNA is detected in respiratory samples but also in blood, stool and urine. Severe COVID-19 is characterized by a dysregulated host ...